GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: Hemay005 | Momishin® (China)
mufemilast is an approved drug
Compound class:
Synthetic organic
|
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Carmona-Rocha E, Rusiñol L, Puig L. (2025)
Exploring the Therapeutic Landscape: A Narrative Review on Topical and Oral Phosphodiesterase-4 Inhibitors in Dermatology. Pharmaceutics, 17 (1). [PMID:39861739] |
|
2. Jing R, Zhi X, Shao L. (2026)
Approvals by the China NMPA in 2025. Nat Rev Drug Discov, [Epub ahead of print]. [PMID:41688808] |
|
3. Li X, Wu X, Huo A, Zeng G, Jones R, Chen R, Wang H. (2026)
Safety, Tolerability, and Pharmacokinetics of Mufemilast, a PDE4 Inhibitor, in Healthy Participants: A First-in-Human Phase 1 Study. Clin Pharmacol Drug Dev, 15 (1): e70005. [PMID:41545329] |